HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes

Reuters

Oct 31

HighTide <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes

HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579107493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579107493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579107493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579107493","market":"fut","top_or_hot":-1,"title":"HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1zytV2:1","article_id":"2579107493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579107493","pubTimestamp":1761869164,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.Disclaimer: This news brief was created by Public Technologies  using generative arti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B","BK1161":"生物科技"},"translate_title":"HighTide Therapeutics报告HTD1801治疗2型糖尿病52周III期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":0.9},"content_text":"HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    \n\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}